Lapteva N - Search Results

1

CCL5 as an adjuvant for cancer immunotherapy.

Lapteva N, Huang XF. Lapteva N, et al. Expert Opin Biol Ther. 2010 May;10(5):725-33. doi: 10.1517/14712591003657128. Expert Opin Biol Ther. 2010. PMID: 20233026 Review.

2

Targeting the intratumoral dendritic cells by the oncolytic adenoviral vaccine expressing RANTES elicits potent antitumor immunity.

Lapteva N, Aldrich M, Weksberg D, Rollins L, Goltsova T, Chen SY, Huang XF. Lapteva N, et al. J Immunother. 2009 Feb-Mar;32(2):145-56. doi: 10.1097/CJI.0b013e318193d31e. J Immunother. 2009. PMID: 19238013 Free PMC article.

3

Attraction and activation of dendritic cells at the site of tumor elicits potent antitumor immunity.

Lapteva N, Aldrich M, Rollins L, Ren W, Goltsova T, Chen SY, Huang XF. Lapteva N, et al. Mol Ther. 2009 Sep;17(9):1626-36. doi: 10.1038/mt.2009.111. Epub 2009 Jun 16. Mol Ther. 2009. PMID: 19532135 Free PMC article.

4

SOCS1 downregulation in dendritic cells promotes memory T-cell responses.

Aldrich M, Sanders D, Lapteva N, Huang XF, Chen SY. Aldrich M, et al. Among authors: lapteva n. Vaccine. 2008 Feb 20;26(8):1128-35. doi: 10.1016/j.vaccine.2007.11.020. Epub 2007 Dec 7. Vaccine. 2008. PMID: 18222020 Free PMC article.

5

A composite MyD88/CD40 switch synergistically activates mouse and human dendritic cells for enhanced antitumor efficacy.

Narayanan P, Lapteva N, Seethammagari M, Levitt JM, Slawin KM, Spencer DM. Narayanan P, et al. Among authors: lapteva n. J Clin Invest. 2011 Apr;121(4):1524-34. doi: 10.1172/JCI44327. Epub 2011 Mar 7. J Clin Invest. 2011. PMID: 21383499 Free PMC article.

6

An essential role for Akt1 in dendritic cell function and tumor immunotherapy.

Park D, Lapteva N, Seethammagari M, Slawin KM, Spencer DM. Park D, et al. Among authors: lapteva n. Nat Biotechnol. 2006 Dec;24(12):1581-90. doi: 10.1038/nbt1262. Epub 2006 Dec 3. Nat Biotechnol. 2006. PMID: 17143278

7

Phase I trial of antigen-targeted autologous dendritic cell-based vaccine with in vivo activation of inducible CD40 for advanced prostate cancer.

Sonpavde G, McMannis JD, Bai Y, Seethammagari MR, Bull JMC, Hawkins V, Dancsak TK, Lapteva N, Levitt JM, Moseley A, Spencer DM, Slawin KM. Sonpavde G, et al. Among authors: lapteva n. Cancer Immunol Immunother. 2017 Oct;66(10):1345-1357. doi: 10.1007/s00262-017-2027-6. Epub 2017 Jun 12. Cancer Immunol Immunother. 2017. PMID: 28608115 Free PMC article. Clinical Trial.

8

Large-Scale Culture and Genetic Modification of Human Natural Killer Cells for Cellular Therapy.

Lapteva N, Parihar R, Rollins LA, Gee AP, Rooney CM. Lapteva N, et al. Methods Mol Biol. 2016;1441:195-202. doi: 10.1007/978-1-4939-3684-7_16. Methods Mol Biol. 2016. PMID: 27177667

9

T-Cell Receptor Stimulation Enhances the Expansion and Function of CD19 Chimeric Antigen Receptor-Expressing T Cells.

Lapteva N, Gilbert M, Diaconu I, Rollins LA, Al-Sabbagh M, Naik S, Krance RA, Tripic T, Hiregange M, Raghavan D, Dakhova O, Rouce RH, Liu H, Omer B, Savoldo B, Dotti G, Cruz CR, Sharpe K, Gates M, Orozco A, Durett A, Pacheco E, Gee AP, Ramos CA, Heslop HE, Brenner MK, Rooney CM. Lapteva N, et al. Clin Cancer Res. 2019 Dec 15;25(24):7340-7350. doi: 10.1158/1078-0432.CCR-18-3199. Epub 2019 Sep 26. Clin Cancer Res. 2019. PMID: 31558475 Free PMC article.

10

CXCR4 knockdown by small interfering RNA abrogates breast tumor growth in vivo.

Lapteva N, Yang AG, Sanders DE, Strube RW, Chen SY. Lapteva N, et al. Cancer Gene Ther. 2005 Jan;12(1):84-9. doi: 10.1038/sj.cgt.7700770. Cancer Gene Ther. 2005. PMID: 15472715

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

102 results

Search Page